このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

CanSino Biologics 将来の成長

Future 基準チェック /56

CanSino Biologics利益と収益がそれぞれ年間124.6%と34.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に5.1% 119.3%なると予測されています。

主要情報

124.6%

収益成長率

119.3%

EPS成長率

Biotechs 収益成長	35.7%
収益成長率	34.3%
将来の株主資本利益率	5.1%
アナリストカバレッジ	Low
最終更新日	04 Jun 2024

今後の成長に関する最新情報

Recent updates

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11

Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

Dec 26

CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly

Oct 01

CanSino Biologics' (HKG:6185) Earnings Aren't As Good As They Appear

Sep 05

Is CanSino Biologics (HKG:6185) Using Debt In A Risky Way?

Jul 03

業績と収益の成長予測

SEHK:6185 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,779	157	288	455	4
12/31/2025	1,213	-5	-58	216	5
12/31/2024	860	-286	-470	-247	5
3/31/2024	371	-1,513	-1,201	-671	N/A
12/31/2023	357	-1,483	-1,519	-908	N/A
9/30/2023	503	-1,420	-1,867	-1,207	N/A
6/30/2023	431	-1,763	-2,339	-1,375	N/A
3/31/2023	636	-1,170	-2,660	-1,599	N/A
12/31/2022	1,035	-909	-2,927	-1,852	N/A
9/30/2022	1,921	106	-1,733	-587	N/A
6/30/2022	2,868	989	-992	68	N/A
3/31/2022	4,332	2,050	328	1,464	N/A
12/31/2021	4,300	1,914	847	2,050	N/A
9/30/2021	3,105	1,113	18	1,065	N/A
6/30/2021	2,082	643	-250	531	N/A
3/31/2021	488	-388	-873	-317	N/A
12/31/2020	25	-397	-638	-350	N/A
9/30/2020	6	-239	-413	-230	N/A
6/30/2020	4	-189	-333	-196	N/A
3/31/2020	6	-135	-310	-164	N/A
12/31/2019	2	-157	-271	-154	N/A
9/30/2019	6	-137	-265	-131	N/A
6/30/2019	11	-156	-280	-140	N/A
3/31/2019	9	-158	-252	-132	N/A
12/31/2018	9	-138	-284	-124	N/A
12/31/2017	9	-64	N/A	-56	N/A
12/31/2016	8	-50	N/A	-34	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 6185は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.2% ) よりも高い成長率であると考えられます。

収益対市場: 6185今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 6185今後 3 年以内に収益を上げることが予想されます。

収益対市場: 6185の収益 ( 34.3% ) Hong Kong市場 ( 7.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: 6185の収益 ( 34.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 6185の自己資本利益率は、3年後には低くなると予測されています ( 5.1 %)。

CanSino Biologics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to CN¥1.19 loss

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Consensus EPS estimates fall by 73%

Recent updates

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Consensus revenue estimates fall by 41%

Investor sentiment deteriorated over the past week

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

CanSino Biologics Inc. to Report Q2, 2022 Results on Aug 26, 2022

Investor sentiment deteriorated over the past week

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Consensus revenue estimates fall by 12%

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Cansino Biologics Inc. Announces Dividend for the Financial Year Ended December 31, 2021 Payable on 19 August 2022

Investor sentiment improved over the past week

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent